First-in-human study of intravenous bispecific CTLA-4 × OX40 antibody (ATOR-1015) in advanced solid malignancies☆ - ESMO Open esmoopen.com/article/S2059-7…
Happy to share new paper highlighting mitazalimabs role in degrading storms and enhancing T cell infiltration in PDAC tumors.
nature.com/articles/s41467-0…
rdcu.be/eSMP7
Mitazalimab plus mFOLFIRINOX in Metastatic Pancreatic Cancer: Insights from the OPTIMIZE-1 Study oncodaily.com/oncolibrary/mi…
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic panc... sciencedirect.com/science/ar…
Happy to share our new article!
ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell–dependent tumor immunity and synergizes with PD-1 blockade aacrjournals.org/cancerimmun…
Thanks to all co-authors!
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies jitc.bmj.com/content/13/1/e0…
Peter Ellmark retweeted
In honor of #InternationalWomensDay, we recognize the following remarkable women who lead important #JITC sections as editors. Thank you! 👏
Dr. Sandra Demaria @WeillCornell
Dr. @MarcelaMaus (MassGen)
Dr. Claudia Palena @theNCI
Dr. Alexandra Snyder @generate_biomed
Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate – Alligator Bioscience alligatorbioscience.se/en/ne…
Peter Ellmark retweeted
Congratulations to #JITC Section Editor Dr. Cornelis "Kees" Melief of @UniLeidenNews for being recognized as this year's Pedro J. Romero Service to JITC Award recipient! Thank you for all of your leadership and for sharing your vision with the journal!
Peter Ellmark retweeted
Prof. Leisha A. Emens MD PHD, incoming President of SITC “The Society is working to put itself out of business” curing #cancer/new VP, Dr James L. Gulley MD PHD - SITC “Family, Friends, Country” THE SOCIETY IS IN GREAT HANDS! @gulleyj1 @theNCI @FDAOncology @sitcancer #SITC2022
Peter Ellmark retweeted
Congratulations to this year's #JITC Best Paper Award recipients - the first authors of top original research papers from the past year! Read the papers using the QR codes and hear more about them during Session 207 in hall 205ABC! #SITC22 @McAuliffe_James @ShrutiGkidney
Peter Ellmark retweeted
The Steven A. Rosenberg Scholar Award Recipient is Dr. @emilykeungMD @MDAndersonNews @JenWargoMD !! #SITC2022 #SITC22 @sitcancer
Very proud to be part of the Alligator team behind this manuscript describing how our Neo-X-Prime technology delivers next generation CD40 targeting therapies
New #JITC article: Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies bit.ly/3DuOa9R @EllmarkPeter
Peter Ellmark retweeted
New #JITC article: Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies bit.ly/3DuOa9R @EllmarkPeter
Peter Ellmark retweeted
Alligator Bioscience starts clinical phase I study with ATOR-1015 bit.se/q8FblR
Peter Ellmark retweeted
Scrip interviewed CEO Per Norlén last week at BIO-Europe on the company's business development strategies and development triggers. youtube.com/watch?v=80yhRt_c… … …
#bioeurope #immunooncology #arevolutionforlife
Peter Ellmark retweeted
Busy days for Alligator at @sitcancer in Washington DC. The three preclinical projects ATOR-1015, ATOR-1017 and ALG.APV-527 all to be showcased at the conference. #immunooncology #arevolutionforlife sitcancer.org/2018/home
Peter Ellmark retweeted
@AlligatorBio Vice President Discovery Peter Ellmark giving a talk in Copenhagen on the topic "Public Private Partnership in Immuno-Oncology" #IOCPH18 #arevolutionforlife
Peter Ellmark retweeted
CEO Per Norlén now on stage @VatorSecurities Unicorn Summit @MediconVillage telling the exciting Alligator story to a high level investor audience. #immunooncology #nextgenerationctla4 #arevolutionforlife